Bluebird partners with Bay Area biotech on new cancer drug targets

The firms said the $30 million deal could produce treatments for cancer patients who are currently without options.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.